- Home
- LMNR vs QTTB Comparison
LMNR vs QTTB Comparison
Compare LMNR & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMNR
- QTTB
- Stock Information
- Founded
- LMNR 1893
- QTTB 2015
- Country
- LMNR United States
- QTTB United States
- Employees
- LMNR N/A
- QTTB N/A
- Industry
- LMNR Farming/Seeds/Milling
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- LMNR Consumer Staples
- QTTB Health Care
- Exchange
- LMNR Nasdaq
- QTTB Nasdaq
- Market Cap
- LMNR 486.1M
- QTTB 434.0M
- IPO Year
- LMNR N/A
- QTTB N/A
- Fundamental
- Price
- LMNR $27.52
- QTTB $27.04
- Analyst Decision
- LMNR Buy
- QTTB Strong Buy
- Analyst Count
- LMNR 2
- QTTB 6
- Target Price
- LMNR $24.00
- QTTB $72.33
- AVG Volume (30 Days)
- LMNR 40.9K
- QTTB 103.1K
- Earning Date
- LMNR 12-19-2024
- QTTB 11-07-2024
- Dividend Yield
- LMNR 1.09%
- QTTB N/A
- EPS Growth
- LMNR N/A
- QTTB N/A
- EPS
- LMNR 0.29
- QTTB N/A
- Revenue
- LMNR $189,075,000.00
- QTTB N/A
- Revenue This Year
- LMNR $7.75
- QTTB N/A
- Revenue Next Year
- LMNR $16.50
- QTTB N/A
- P/E Ratio
- LMNR $93.91
- QTTB N/A
- Revenue Growth
- LMNR 6.15
- QTTB N/A
- 52 Week Low
- LMNR $15.15
- QTTB $9.18
- 52 Week High
- LMNR $29.22
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- LMNR 55.24
- QTTB 18.25
- Support Level
- LMNR $25.75
- QTTB $26.00
- Resistance Level
- LMNR $26.92
- QTTB $51.26
- Average True Range (ATR)
- LMNR 0.93
- QTTB 4.00
- MACD
- LMNR -0.05
- QTTB -2.12
- Stochastic Oscillator
- LMNR 57.50
- QTTB 4.12
About LMNR Limoneira Co
Limoneira Co is an agribusiness company. The company's operating segments include Fresh Lemons; Lemon Packing; Avocados and Other Agribusiness. It generates maximum revenue from the Fresh Lemons segment.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.